Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2017 February;108(1) > Minerva Medica 2017 February;108(1):57-73

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW   

Minerva Medica 2017 February;108(1):57-73

DOI: 10.23736/S0026-4806.16.04759-5

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cumulative review and meta-analyses on the association between MTHFR rs1801133 polymorphism and breast cancer risk: a pooled analysis of 83 studies with 74,019 participants

Yun ZHANG 1, Hongjun JIA 2, Shoufeng WANG 1, Dazhi JIANG 3

1 Department of Oncology, Linyi Peoples’ Hospital, Linyi, China; 2 Department of Radiotherapy, Linyi Peoples’ Hospital, Linyi, China; 3 Department of Thoracic Surgery, Linyi Peoples’ Hospital, Linyi, China


PDF


BACKGROUND: The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been extensively explored, but their results are conflicting rather than conclusive. To clarify the precise effects of MTHFR polymorphisms on the risk of breast cancer, a systemic review and most comprehensive meta-analysis of all available studies relating MTHFR rs1801133 gene polymorphism to the risk of breast cancer was conducted.
METHODS: Eligible articles were identified by search of databases including Medline (Mainly PubMed), Embase, Web of Science, Chinese Biomedical Literature database (CBM), CNKI and Wanfang Medical databases. Crude ORs with 95% CIs were used to assess the strength of association.
RESULTS: Finally, a total of 83 studies with 35,029 cases and 38,990 controls were included. Overall, MTHFR rs1801133 gene polymorphism was proved to contribute to the risk of breast cancer under all genetic models (TT vs. CC: Pheterogeneity <0.001, OR=1.141, 95%CI=1.065-1.222, P <0.001; TT vs. CT: Pheterogeneity <0.001, OR=1.085, 95%CI=1.021-1.154, P=0.009; TT + CT vs. CC: Pheterogeneity <0.001, OR=1.040, 95%CI=1.020-1.061, P <0.001; TT vs. CC + CT: Pheterogeneity <0.001, OR=1.131, 95%CI=1.052-1.215, P=0.0478; T allele vs. C allele: Pheterogeneity <0.001, OR=1.040, 95%CI=1.009-1.071, P=0.010).
CONCLUSIONS: The results of this meta-analysis suggest that MTHFR rs1801133 gene polymorphism may the therapeutic target for breast cancer.


KEY WORDS: MTHFR protein, human - Polymorphism, genetic - Breast neoplasms - Disease susceptibility - Meta-analysis

inizio pagina